Company Encyclopedia
View More
name
Third Harmonic Bio
THRD.US
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG.
4.715 T
THRD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Third Harmonic Bio Inc. Announces Voluntary Delisting from Nasdaq and Plans to Terminate SEC Reporting Obligations

    Third Harmonic Bio Inc. has announced its voluntary delisting from Nasdaq, effective around August 10, 2025, following the filing of a Form 25 with the SEC on July 31, 2025. Trading of its stock was suspended on the same day. The company also plans to file a Form 15 to terminate its SEC reporting obligations as part of its approved Plan of Dissolution, with a certificate of dissolution filed concurrently.

    Reuters·
    US
    THRD
    0.00%
    Reuters·
    US
    THRD
    0.00%

    Third Harmonic Bio Inc. Stockholders Approve Liquidation Plan, Initiates Sale of THB335 Asset

    Third Harmonic Bio, Inc. has received stockholder approval for its liquidation plan, initiating the sale of its asset THB335, an oral wild-type KIT inhibitor. The Phase 1 trial showed an 85% reduction in serum tryptase, paving the way for a Phase 2 trial pending FDA clearance. Stockholders can expect an initial distribution of $5.30 to $5.35 per share in Q3 2025. Interested buyers should contact Chris Murphy for details.

    Reuters·
    US
    THRD
    0.00%
    Reuters·
    US
    THRD
    0.00%

    Third Harmonic Bio Inc. Conducted Annual Stockholders Meeting

    Third Harmonic Bio Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025, where several proposals were adopted. The meeting approved the election of three Class III directors, the appointment of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and the liquidation and dissolution of the Company. Additionally, the Board was granted discretionary authority to adjourn the meeting to solicit additional proxies if needed.

    Reuters·
    US
    THRD
    0.00%
    Reuters·
    US
    THRD
    0.00%

    Third Harmonic Bio Inc reports results for the quarter ended March 31 - Earnings Summary

    Third Harmonic Bio Inc reported a quarterly adjusted loss of 35 cents per share for the quarter ended March 31, compared to a loss of 20 cents per share in the same quarter last year. The reported revenue was zero, matching analyst expectations. The company incurred a quarterly loss of $15.83 million. Analysts have revised earnings estimates down by 4.9% over the last three months. The average analyst rating is "hold" with a median 12-month price target of $5.23. Shares rose 48.7% this quarter but are down 49.9% year-to-date.

    Reuters·
    US
    THRD
    0.00%
    Reuters·
    US
    THRD
    0.00%

    Third Harmonic Bio Inc <Q> expected to post a loss of 31 cents a share - Earnings Preview

    Third Harmonic Bio Inc is expected to report a loss of 31 cents per share for the quarter ending March 31, 2025. Analysts predict no change in quarterly revenue, with a current average rating of "hold". The mean earnings estimate has increased by 5.6% over the last three months. Wall Street's median 12-month price target is $5.23, slightly above the last closing price of $5.15. Previous quarterly performances show mixed results, with several misses and beats in earnings estimates.

    Reuters·
    US
    THRD
    0.00%
    Reuters·
    US
    THRD
    0.00%
    © 2025 Longbridge｜Disclaimer